iX Biopharma Balance Sheet Health

Financial Health criteria checks 3/6

iX Biopharma has a total shareholder equity of SGD4.3M and total debt of SGD4.7M, which brings its debt-to-equity ratio to 107.6%. Its total assets and total liabilities are SGD14.6M and SGD10.3M respectively.

Key information

107.6%

Debt to equity ratio

S$4.67m

Debt

Interest coverage ration/a
CashS$1.84m
EquityS$4.34m
Total liabilitiesS$10.28m
Total assetsS$14.62m

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 42C's short term assets (SGD6.6M) do not cover its short term liabilities (SGD7.4M).

Long Term Liabilities: 42C's short term assets (SGD6.6M) exceed its long term liabilities (SGD2.9M).


Debt to Equity History and Analysis

Debt Level: 42C's net debt to equity ratio (65.1%) is considered high.

Reducing Debt: 42C's debt to equity ratio has increased from 18.7% to 107.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 42C has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: 42C is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies